 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5515 News |  |
| «12...58596061626364656667686970» |
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - Dec 5, 2015
P2, N=213, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: PETRA: Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) (clinicaltrials.gov) - Dec 4, 2015
P1, N=30, Recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Jun 2016
- ||| New P1 trial, Combination therapy: Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer (clinicaltrials.gov) - Dec 3, 2015
P1, N=59, Recruiting, Sponsor: Hoffmann-La Roche
- ||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Nov 21, 2015
P3, N=1846, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Active, not recruiting | N=2500 --> 1846
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, BRCA Biomarker: Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov) - Nov 19, 2015
P2, N=30, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=2500 --> 1846 Trial primary completion date: Mar 2015 --> Mar 2017
- ||| New P1 trial, Combination therapy: Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer (clinicaltrials.gov) - Nov 16, 2015
P1, N=66, Recruiting, Sponsor: Hoffmann-La Roche
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial primary completion date, Metastases: HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy (clinicaltrials.gov) - Nov 10, 2015
P=N/A, N=262, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2015 --> Mar 2017 N=478 --> 262 | Trial primary completion date: Sep 2018 --> Mar 2019
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: EORTC-75111-10114: Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 (clinicaltrials.gov) - Nov 9, 2015
P2, N=80, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=478 --> 262 | Trial primary completion date: Sep 2018 --> Mar 2019 Trial primary completion date: Nov 2016 --> Apr 2016
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1 trial: Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer (clinicaltrials.gov) - Nov 6, 2015
P1, N=36, Not yet recruiting, Sponsor: Duke University
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Nov 5, 2015
P2, N=401, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2016 --> Apr 2016 Recruiting --> Active, not recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: PATRICIA: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (clinicaltrials.gov) - Nov 3, 2015
P2, N=40, Recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2019 --> Dec 2018
- Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma, Perjeta (pertuzumab) / Roche
New P1 trial, Combination therapy, Metastases: Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ (clinicaltrials.gov) - Nov 2, 2015
P1, N=40, Recruiting, Sponsor: Michelle Melisko
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer (clinicaltrials.gov) - Oct 29, 2015
P2, N=88, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Mar 2019 --> Dec 2018 Trial primary completion date: Jan 2016 --> Jan 2017
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial, Combination therapy, Surgery, Metastases: PEONY: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (clinicaltrials.gov) - Oct 26, 2015
P3, N=328, Not yet recruiting, Sponsor: Hoffmann-La Roche
- Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: TEAL: Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel (clinicaltrials.gov) - Oct 22, 2015
P2, N=30, Recruiting, Sponsor: The Methodist Hospital System
Trial primary completion date: Jan 2016 --> Jan 2017 Trial primary completion date: Jun 2015 --> Jun 2017
- carboplatin / Generic mfg., docetaxel / Generic mfg.
Metastases: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov) - Oct 22, 2015
P3, N=312, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Jun 2017 Trial primary completion date: Jan 2017 --> Mar 2018
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=30, Suspended, Sponsor: University of Washington
Trial primary completion date: Jan 2017 --> Mar 2018 Trial primary completion date: Sep 2015 --> Sep 2016
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib (clinicaltrials.gov) - Oct 22, 2015
P0, N=40, Recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: May 2015 --> Mar 2017
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=95, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: May 2015 --> Mar 2017 Trial primary completion date: Dec 2017 --> Feb 2008
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2/3 trial: PETRARCA: FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (clinicaltrials.gov) - Oct 22, 2015
P2/3, N=404, Not yet recruiting, Sponsor: Krankenhaus Nordwest
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
New P2/3 trial: PREDIX HER2: Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer (clinicaltrials.gov) - Oct 6, 2015
P2/3, N=200, Recruiting, Sponsor: Thomas Hatschek
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - Oct 3, 2015
P2, N=213, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2017 --> Feb 2008 Trial primary completion date: Jun 2016 --> Nov 2015 | Recruiting --> Active, not recruiting
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Oct 3, 2015
P2, N=257, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2016 --> Nov 2015 | Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> Oct 2019
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: PATRICIA: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (clinicaltrials.gov) - Oct 2, 2015
P2, N=40, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Oct 2016 --> Oct 2019 Trial primary completion date: Dec 2018 --> Mar 2019
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: INNOVATION: Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Sep 30, 2015
P2, N=220, Recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Dec 2018 --> Mar 2019 Not yet recruiting --> Recruiting
- | carboplatin / Generic mfg., docetaxel / Generic mfg.
Metastases: Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer (clinicaltrials.gov) - Sep 29, 2015
P3, N=312, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=212 --> 312
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Metastases: PATRICIA: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (clinicaltrials.gov) - Sep 27, 2015
P2, N=40, Recruiting, Sponsor: Genentech, Inc.
N=212 --> 312 Not yet recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Trial termination, Trial primary completion date: STEFNE: Fasting on Newly Diagnosed Breast Cancer (clinicaltrials.gov) - Sep 25, 2015
P1/2, N=9, Terminated, Sponsor: Western Regional Medical Center
Not yet recruiting --> Recruiting N=40 --> 9 | Recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Aug 2015; PI Decision
- || Biomarker, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker, Metastases: MODUL: A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Sep 24, 2015
P2, N=610, Recruiting, Sponsor: Hoffmann-La Roche
N=40 --> 9 | Recruiting --> Terminated | Trial primary completion date: Jan 2016 --> Aug 2015; PI Decision Trial primary completion date: Mar 2019 --> Dec 2018
- Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) - Sep 24, 2015
P2, N=208, Recruiting, Sponsor: Swiss Group for Clinical Cancer Research
Trial primary completion date: Mar 2019 --> Dec 2018 Trial primary completion date: Jun 2015 --> Nov 2017
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: JACOB: A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer (clinicaltrials.gov) - Sep 24, 2015
P3, N=780, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2015 --> Nov 2017 Trial primary completion date: Mar 2022 --> Sep 2021
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer (clinicaltrials.gov) - Sep 24, 2015
P2, N=210, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Mar 2022 --> Sep 2021 Trial primary completion date: Nov 2015 --> Jun 2016
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Combination therapy, Metastases: Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer (clinicaltrials.gov) - Sep 2, 2015
P4, N=52, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- |||||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Sep 2, 2015
P3, N=270, Recruiting, Sponsor: Prof. W. Janni
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: NeoTOP: Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status (clinicaltrials.gov) - Sep 1, 2015
P2, N=90, Recruiting, Sponsor: UNICANCER
Not yet recruiting --> Recruiting | Initiation date: Apr 2015 --> Sep 2015 | Trial primary completion date: Mar 2021 --> Sep 2021 Not yet recruiting --> Recruiting
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial, Metastases: PATRICIA: A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy (clinicaltrials.gov) - Aug 31, 2015
P2, N=40, Not yet recruiting, Sponsor: Genentech, Inc.
- Ibrance (palbociclib) / Pfizer
New P2 trial: NA-PHER2: "Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment " (clinicaltrials.gov) - Aug 21, 2015
P2, N=32, Recruiting, Sponsor: Fondazione Michelangelo
- ||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer (clinicaltrials.gov) - Aug 19, 2015
P3, N=1438, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial suspension, IO biomarker, Metastases: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=30, Suspended, Sponsor: University of Washington
Recruiting --> Active, not recruiting Recruiting --> Suspended
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial initiation date, Trial primary completion date: INNOVATION: Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Aug 13, 2015
P2, N=220, Not yet recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Suspended Initiation date: Dec 2014 --> Sep 2015 | Trial primary completion date: Dec 2019 --> Sep 2020
- Perjeta (pertuzumab) / Roche
Enrollment change, Metastases: Safety Study of rhuMAb 2C4 to Treat Advanced Solid Tumors (clinicaltrials.gov) - Aug 13, 2015
P1, N=21, Completed, Sponsor: Genentech, Inc.
Initiation date: Dec 2014 --> Sep 2015 | Trial primary completion date: Dec 2019 --> Sep 2020 N=30 --> 21
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: PERTAIN: A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer (clinicaltrials.gov) - Aug 12, 2015
P2, N=258, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=30 --> 21 Recruiting --> Active, not recruiting
- |||||||||| Perjeta (pertuzumab) / Roche
New P3 trial, Metastases: PRECIOUS: A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Aug 4, 2015
P3, N=370, Not yet recruiting, Sponsor: Japan Breast Cancer Research Group
- | Perjeta (pertuzumab) / Roche
New P1 trial, Combination therapy, Metastases: A Study of Pertuzumab in Combination With Erlotinib (Tarceva) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 3, 2015
P1, N=17, Completed, Sponsor: Hoffmann-La Roche
- Perjeta (pertuzumab) / Roche
New P1 trial, Metastases: A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 23, 2015
P1, N=17, Completed, Sponsor: Hoffmann-La Roche
- Perjeta (pertuzumab) / Roche
New P1 trial, Metastases: A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 10, 2015
P1, N=19, Completed, Sponsor: Hoffmann-La Roche
- | Perjeta (pertuzumab) / Roche
New P2 trial, Metastases: A Study of Pertuzumab in Participants With Metastatic Breast Cancer (clinicaltrials.gov) - Jul 8, 2015
P2, N=79, Completed, Sponsor: Hoffmann-La Roche
- |||| Perjeta (pertuzumab) / Roche
Trial completion, Metastases: Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy (clinicaltrials.gov) - Jul 7, 2015
P2, N=51, Completed, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- Perjeta (pertuzumab) / Roche
New P1 trial, Metastases: A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors (clinicaltrials.gov) - Jul 6, 2015
P1, N=19, Completed, Sponsor: Hoffmann-La Roche
- | Enrollment closed: KRISTINE: A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Jul 6, 2015
P3, N=444, Active, not recruiting, Sponsor: Hoffmann-La Roche
No longer recruiting --> Completed Recruiting --> Active, not recruiting